TSTickerStarGet alerts

FEMY 10-Q filed 2026-11-13 | Key takeaways

FEMY filed its 10-Q; the most relevant disclosure change is expanded Liquidity and capital resources: Cash and cash equivalents increased to $23.9M as of September 30, 2026 from $1.4M as of June 30, 2026, primarily due to $30M gross proceeds from August 2026 private placement. Company believes its cash will fund operations for at least twelve months from finan.

Share this story

Key takeaways

  • Sales: Q3 2026 sales of $405K decreased 44.5% year-over-year from $729K, reflecting anticipated timing of international FemBloc orders as distributors utilize existing inventory for post-market studies.

  • Net loss: Q3 2026 net loss of $4.6M compared to $4.2M in Q3 2025; nine-month net loss improved to $8.2M from $14.7M in prior year, a 44.2% improvement.

  • Liquidity: Cash increased to $23.9M at September 30, 2026 from $1.4M at June 30, 2026 following August 2026 private placement of common stock, pre-funded warrants, and warrants generating $30M gross ($27.4M net) proceeds.

  • Derivative liabilities reclassified: Conversion option and warrants liabilities of approximately $1.0M were reclassified to equity in April 2026 following shareholder approval, eliminating recurring fair value adjustments.

  • Legal matter: On September 2, 2026, Iroquois Master Fund and Iroquois Capital Investment Group filed for summary judgment alleging the August 2026 financing constituted a Fundamental Transaction under the 2025 Notes, seeking approximately $3.1M plus interest and fees; company believes claims are without merit.

  • Board change: Kenneth D. Eichenbaum, M.D., M.S.E. resigned as director effective October 30, 2026; John Moorhead appointed to replace him.

  • EPS: Basic and diluted loss per share was $(0.53) for Q3 2026 compared to $(2.05) for Q3 2025, reflecting reverse stock split and improved net loss; nine-month EPS was $(1.59) versus $(9.25) in prior year.

Key metrics

SalesQ3 2026
$404,597-44.5%
SalesNine months 2026
$1,161,313-21.5%
Net lossQ3 2026
$4,564,8158.8% increase in loss
Net lossNine months 2026
$8,187,810-44.2%
Basic and diluted loss per shareQ3 2026
$(0.53)improved from $(2.05)
Basic and diluted loss per shareNine months 2026
$(1.59)improved from $(9.25)
Cash and cash equivalentsSeptember 30, 2026
$23,913,946up from $4,569,038
Weighted-average shares outstandingQ3 2026
8,660,381up from 2,050,761

Disclosure changes

  • Liquidity and capital resources

    Cash and cash equivalents increased to $23.9M as of September 30, 2026 from $1.4M as of June 30, 2026, primarily due to $30M gross proceeds from August 2026 private placement. Company believes its cash will fund operations for at least twelve months from financial statement issuance date.

    Significant improvement in liquidity position; company no longer dependent on additional financing for near-term operations.
  • Convertible notes and derivative liabilities

    Conversion option liability and warrants liabilities of approximately $1.0M were reclassified to equity in April 2026 following shareholder approval, eliminating recurring fair value measurement. The 2025 Notes have face value of $11.9M with 8.5% PIK interest, effective interest rate of 21.9%, and mature November 2035.

    Derivative liabilities removed from balance sheet; fair value changes no longer flowing through earnings.
  • Legal proceedings

    On September 2, 2026, Iroquois Master Fund, Ltd. and Iroquois Capital Investment Group LLC filed motion for summary judgment alleging the August 2026 financing constituted a Fundamental Transaction under the 2025 Notes, seeking approximately $3.1M plus prejudgment interest and attorneys' fees. Company believes allegations are without merit and intends to defend vigorously; no accrual recorded.

    Potential cash obligation of $3.1M+ if plaintiffs prevail; company disputes claims.
  • Stockholders' equity

    Stockholders' equity increased to $27.0M as of September 30, 2026 from $4.0M as of June 30, 2026, driven by August 2026 financing net proceeds of $27.4M and reclassification of derivative liabilities to equity. Common shares outstanding increased to 8,656,277 from 3,023,967.

    Significant increase in equity provides financial flexibility but reflects substantial dilution to existing shareholders.
  • Revenue recognition and sales concentration

    Q3 2026 sales of $405K decreased 44.5% year-over-year due to timing of international FemBloc orders; U.S. sales increased slightly to $347K from $337K. International sales were $58K in Q3 2026 versus $393K in Q3 2025. Distributors utilizing existing inventory for post-market studies with reorders expected after studies complete.

    International sales volatility due to bulk-ordering patterns; U.S. commercial sales showing slight growth.
  • Subsequent events

    On October 30, 2026, Kenneth D. Eichenbaum, M.D., M.S.E. resigned as director and John Moorhead was appointed to replace him effective the same date.

    Board composition change following quarter-end.

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow FEMY in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert